lung cancer

[Cell Death & Disease] Scientists evaluated the specific regulatory mechanisms of exosomal miR-338-3p/CHL1/MAPK signaling pathway axis in NSCLC. In vitro MTS and apoptotic assays were used to investigate the functions of CHL1 and exosomal miR-338-3p in NSCLC progression.

[Cancer Science] The expression of endogenous HRP-3 in human lung cancer tissues and xenograft tumor models is indicative of its clinical relevance in lung cancer. Scientists demonstrated that HRP-3 directly bound to the E2F1 promoter on chromatin.

[Science Immunology] Researchers used an orthotopic non–small cell lung cancer mouse model to study immune checkpoint blockade-refractory CD8+ T cell responses.

[Expert Opinion On Therapeutic Targets] Fusions in neuregulin 1 (NRG1) and neuregulin 2 (NRG2) genes are molecular features of non-small cell lung cancer. These rearrangements enhance ectopic expression of the NRG/ErbB receptor‐ligand and induce the triggering of downstream pathways.

[Cell Death & Disease] Ephexin1 was reported to be highly upregulated by oncogenic Ras, but the functional consequences of this remain poorly understood. The authors showed that Ephexin1 was highly expressed in colorectal cancer and lung cancer patient tissues.

[Cell Reports] The ABL tyrosine kinases promote metastasis, and enhanced ABL signaling is associated with a poor prognosis in lung adenocarcinoma patients. Researchers showed that ABL kinase allosteric inhibitors impaired mitochondrial integrity and decrease oxidative phosphorylation.